Pharmaceutical Strategic Initiatives (PSI) has hired Jeffrey New, BS, PharmD, as vice president of medical activities. He will be based in RTP.
New brings more than 17 years of pharmaceutical experience to PSI. His most recent work includes senior management responsibilities related to medical information, field-based medical liaisons, drug development strategy, drug safety/pharmacovigilance, and medical education and publications.
PSI’s founder and president, Charles Carter, called New an innovator in medical affairs, bringing valuable clinical and industry experience in the life sciences to PSI.
“We are the most experienced provider of strategic services across the pharmaceutical, biotech, and medical device industry,” said Carter. “Jeff brings the clinical and industry experience that the Medical Affairs Departments of our corporate clients require to successfully development and implement their integrated medical affairs strategies.”
PSI offers medical affairs strategic consulting and content development services to the pharmaceutical, biotech and medical device industry.
“PSI is the smartest, fastest and safest solution for providing strategic services to emerging biotech, medical and pharmaceutical companies that are on the cutting edge of research,” added New. “I look forward to helping our clients bring life saving medicines and medical devices to production.”
Prior to joining PSI, New was director of medical and scientific affairs at DEY, L.P., Inc, a subsidiary of Mylan Inc. in Napa, Calif.
